QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

被引：0
作者：
P Ghatalia
Y Je
M D Kaymakcalan
G Sonpavde
T K Choueiri
机构：
[1] University of Alabama at Birmingham (UAB),Department of Internal Medicine
[2] Kyung Hee University,Department of Food and Nutrition
[3] Dana Farber Cancer Institute and Harvard Medical School,Department of Internal Medicine
[4] Section of Medical Oncology,undefined
[5] UAB Medical Center,undefined
来源：
British Journal of Cancer | 2015年 / 112卷
关键词：
vascular endothelial growth factor receptor; tyrosine kinase inhibitors; approved; QTc interval prolongation; meta-analysis; cardiac toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：296 / 305
页数：9
相关论文
共 50 条
  • [41] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects
    Dickerson, Henry
    Diab, Ahmad
    Al Musaimi, Othman
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (18)
  • [42] Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma
    Go, Heounjeong
    Kang, Mun Jung
    Kim, Pil-Jong
    Lee, Jae-Lyun
    Park, Ji Y.
    Park, Ja-Min
    Ro, Jae Y.
    Cho, Yong Mee
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) : 51 - 58
  • [43] Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials
    Li, Jing
    Gu, Jian
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (10) : 1209 - 1217
  • [44] Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials
    Jing Li
    Jian Gu
    European Journal of Clinical Pharmacology, 2017, 73 : 1209 - 1217
  • [45] Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials
    Qi, W. -X.
    Tang, L. -N.
    Sun, Y. -J.
    He, A. -N.
    Lin, F.
    Shen, Z.
    Yao, Y.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 2943 - 2952
  • [46] Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma
    Li, Wei
    Feng, Chengguan
    Di, Weihong
    Hong, Shanwen
    Chen, Hui
    Ejaz, Mubashir
    Yang, Yang
    Xu, Tian-rui
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 200
  • [47] Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors
    Wong, Kwok-Kin
    LUNG CANCER, 2008, 60 : S10 - S18
  • [48] Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
    Abunada, Aya
    Sirhan, Zaid
    Thyagarajan, Anita
    Sahu, Ravi P.
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2023, 14 (05): : 198 - 202
  • [49] EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG.
    Ameratunga, Malaka
    Broad, Adam
    Pavlakis, Nick
    Gebski, Val
    Khasraw, Mustafa
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1189 - S1189
  • [50] Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wildtype non-small cell lung cancer?
    Arriola, Edurne
    Taus, Alvaro
    Casadevall, David
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 45 - 56
12345